Home › NCT06312748
Novel Approaches for Improving Vascular Function in Veterans With HFpEF
RecruitingPhase 1
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age 18 years or older and able to give written informed consent. * New York Heart Association (NYHA) functional class I, II, or III. * Left Ventricular Ejection Fraction (LVEF) \> 50%. * Plasma Brain Natriuretic Peptide (BNP) equal to or greater than 150 pg/mL or NT-proBNP equal to or greater than 600 pg/mL at Visit 1, or a BNP equal to or great than 100 pg/mL (or NT-proBNP equal to or greater than 400 pg/mL) and a hospitalization for heart failure within the last 12 months. Exclusion Criteria: * History of hypersensitivity or allergy to any lipophilic statin. * Prior EF \<50%. * NYHA Class IV. * Patients with HFpEF secondary to significant uncorrected primary valvular disease. * Active liver disease or unexplained persistent elevations in serum transaminase. * Women who are pregnant or may become pregnant. * Patients currently treated with antioxidants, nitrates, PDE-5 inhibitors, or statins.
About the study
This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF).
What is being tested
- L-Citrulline (drug)
- Placebo for L-Citrulline (drug)
- BH4 (drug)
- Placebo for BH4 (drug)
- Atorvastatin (drug)
- Placebo for Atorvastatin (drug)
Sponsor: VA Office of Research and Development · Participants: 90 · Started: May 19, 2021
Contact the study team
- David W Wray, PhD · Phone: (801) 582-1565
- Misti R Seppi, MBA BS AAS · Phone: (801) 582-1565
Official record on ClinicalTrials.gov — NCT06312748
Locations in the U.S.
| Utah | VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.